MiNK Therapeutics (NASDAQ:INKT) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of MiNK Therapeutics (NASDAQ:INKT) from a sell rating to a hold rating in a research note released on Saturday morning.

Several other research firms have also commented on INKT. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of MiNK Therapeutics in a research note on Wednesday, April 1st. Weiss Ratings lowered shares of MiNK Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, MiNK Therapeutics has a consensus rating of “Hold” and a consensus target price of $35.00.

MiNK Therapeutics Stock Performance

NASDAQ INKT opened at $10.72 on Friday. The firm has a 50 day simple moving average of $11.00 and a 200-day simple moving average of $11.61. MiNK Therapeutics has a one year low of $6.65 and a one year high of $76.00. The firm has a market cap of $53.39 million, a price-to-earnings ratio of -3.77 and a beta of 0.47.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.20. Equities analysts predict that MiNK Therapeutics will post -3.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in MiNK Therapeutics stock. DRW Securities LLC purchased a new position in MiNK Therapeutics, Inc. (NASDAQ:INKT) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics as of its most recent SEC filing. 2.87% of the stock is owned by institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.